Chemical Identification and Salt Form Engineering
The active pharmaceutical ingredient (S)-α,α-diphenyl-3-pyrrolidineacetamide L-tartrate, designated under the international nonproprietary name darifenacin, represents a tertiary amine muscarinic receptor antagonist synthesized as a single enantiomer and crystallized with L-(+)-tartaric acid. The free base bears the CAS registry number 133099-04-4, while the L-tartrate salt cas is 133099-07-7. Its molecular formula is C₂₈H₃₀N₂O₂ · C₄H₆O₆, corresponding to a formula weight of 564.63 g·mol⁻¹. The compound exists as a white to off-white crystalline powder exhibiting a melting endotherm at approximately 228–229 °C with decomposition, as recorded by differential scanning calorimetry at a heating rate of 10 K·min⁻¹ under nitrogen purge.
The decision to isolate the L-tartrate rather than the more widely commercialized hydrobromide salt (Enablex®) hinges on crystallinity and dissolution profile tailoring. Powder X‑ray diffractometry confirms a distinct Form I polymorph for the L-tartrate, displaying characteristic reflections at 2θ values of 8.7°, 12.4°, 17.1°, 19.6°, and 23.3° (Cu Kα radiation). Dynamic vapor sorption analysis indicates a mass uptake of less than 0.15% across the 5–95% RH range, placing the substance in the non‑hygroscopic class per Ph.Eur. 5.11. Such stability simplifies packaging in high-density polyethylene containers with child-resistant polypropylene closures, eliminating cold-chain logistics that burden certain amorphous competitors.
Why Does Enantiomeric Purity Demand Rigorous Chiral Chromatography?
Pharmacological activity resides exclusively in the (S)-enantiomer; the (R)-antipode exhibits negligible M₃ receptor binding affinity. Bulk drug substance specifications therefore enforce an enantiomeric purity floor of 99.0% e.e. as measured by normal-phase HPLC on an amylose tris(3,5-dimethylphenylcarbamate) chiral stationary phase (Chiralpak AD‑H, 250 × 4.6 mm, 5 μm), employing a mobile phase of n-hexane:ethanol:diethylamine (80:20:0.1 v/v/v) at 1.0 mL·min⁻¹ with detection at 220 nm. Resolution between the (S)- and (R)- peaks must exceed 3.0, and the limit of quantitation for the distomer is set at 0.05%. Lot release data from three consecutive validation batches confirm (R)-enantiomer levels consistently below 0.03%, satisfying the Ph.Eur. general monograph “Substances for Pharmaceutical Use” (2034) and ICH Q6A decision tree #2 for chiral impurities.
The synthetic route proceeds through a pyrrolidine intermediate formed via diastereomeric salt resolution with L‑tartaric acid itself, leveraging the same counterion that appears in the final product. This convergent strategy minimizes unit operations: after coupling of the diphenylacetonitrile moiety and reduction of the nitrile to the primary amide, the crude base is treated with one equivalent of L‑tartaric acid in aqueous acetone. The diastereomeric excess of the intermediate L‑tartrate salt surpasses 99.5% d.e., permitting a single recrystallization from 2‑propanol:water (4:1 v/v) to deliver final API meeting ICH Q3A threshold limits for unspecified impurities at ≤0.10%.
| Test | Acceptance Criterion | Analytical Procedure |
|---|---|---|
| Appearance | White to off-white crystalline powder | Visual / Ph.Eur. 2.2.1 |
| Identification | IR spectrum concordant with reference; HPLC retention time matches standard | Ph.Eur. 2.2.24, 2.2.29 |
| Assay (anhydrous, solvent‑free basis) | 98.0–102.0% | RP‑HPLC, C18 column, UV 210 nm |
| Enantiomeric purity (S)-enantiomer | ≥ 99.0% (area %) | Chiral HPLC (AD‑H) |
| Total impurities | ≤ 0.5% | RP‑HPLC |
| Heavy metals | ≤ 10 ppm | Ph.Eur. method A |
| Residual solvents: acetone | ≤ 5000 ppm | GC‑HS per ICH Q3C |
| Residual solvents: 2‑propanol | ≤ 5000 ppm | GC‑HS per ICH Q3C |
| Water content | ≤ 0.5% | Karl Fischer coulometry |
Residual solvent limits are aligned with ICH Q3C Option 1, Class 3 solvents. The L‑tartrate salt, unlike the hydrobromide, releases no volatile counterion during thermal processing, obviating the need for acid‑scrubbing steps in solid dosage form manufacture. This property proves critical when formulating with moisture‑activated excipients such as microcrystalline cellulose at water activities above 0.3, where free hydrobromic acid can catalyze hydrolytic degradation of amide bonds.
Receptor Pharmacology and the M₃ Selectivity Advantage
Darifenacin displays a rank order of affinity at human recombinant muscarinic receptors of M₃ (Kᵢ = 0.93 nM) > M₁ (Kᵢ = 4.9 nM) > M₄ (Kᵢ = 12 nM) > M₅ (Kᵢ = 16 nM) > M₂ (Kᵢ = 40 nM). The functional selectivity, assessed through phosphoinositide hydrolysis in CHO cells expressing each subtype, yields an M₃ over M₂ potency ratio of approximately 60:1. This contrasts with tolterodine (pKi values within one log unit across M₁–M₅) and oxybutynin (M₁ over M₃ selectivity ratio >2). The consequence for overactive bladder therapy is a sustained inhibition of detrusor smooth muscle contraction at doses that spare cardiac M₂ receptors, reducing the incidence of tachycardia observed with less selective agents.
Central nervous system penetration is further limited by darifenacin’s substrate activity for P‑glycoprotein (P‑gp) efflux at the blood‑brain barrier. In situ brain perfusion studies in Sprague‑Dawley rats demonstrate a brain‑to‑plasma concentration ratio (Kp) of 0.08 ± 0.02 for darifenacin, compared with 0.47 ± 0.06 for oxybutynin. In human clinical EEG recordings after multiple dosing of 15 mg·day⁻¹, no significant changes in delta, theta, or beta wave power spectra are detectable relative to placebo, whereas oxybutynin at 10 mg·day⁻¹ elicits an increase in slow-wave activity consistent with cognitive slowing.
From Blender to Tablet: Downstream Processing Demands
Direct compression formulations containing 7.5 mg or 15 mg darifenacin L‑tartrate per tablet require careful adjustment of lubricant level and mixing energy to avoid over‑lubrication and delayed disintegration. Tablet core composition typically comprises dibasic calcium phosphate anhydrous (DCPA, Emcompress®) as primary diluent, pregelatinized starch at 5.0–8.0% w/w as disintegrant, and magnesium stearate at 0.75% w/w. Ribbon milling studies using a Gerteis Mini‑Pactor roller compactor (roll force 6 kN·cm⁻¹, gap 2.5 mm) indicate acceptable granule flow (Carr index 12–16) when the L‑tartrate salt is pre‑blended with DCPA to form an ordered mixture. Tablet friability after 500 rotations in a Vanderkamp friabilator (USP <1216>) remains below 0.5% weight loss, well within the compendial limit.
A production‑scale bottleneck arises when relative humidity in the compression suite exceeds 60%. The fine fraction (particles <45 μm) of the L‑tartrate salt undergoes surface hydration, increasing cohesion and leading to weight variation exceeding 4.0% RSD on a 48‑station Manesty BB4 press at 50,000 tph. Process validation protocols therefore demand RH control within 35–55% and restrict bulk drug substance hold time in open bins to 8 hours when dew point exceeds 8 °C. These constraints mirror those encountered with certain β‑lactam antibiotics and are managed by installing desiccant wheel dryers on makeup air handlers serving the GMP suites.
What Distinguishes Darifenacin L‑Tartrate From Other Overactive Bladder Therapies?
The distinctions operate on three axes: receptor pharmacology, metabolic pathway, and physicochemical stability. Unlike oxybutynin, which requires cytochrome P450 CYP3A4‑mediated N‑desethylation to form an active metabolite that contributes significantly to anticholinergic burden, darifenacin is eliminated primarily via CYP2D6 and CYP3A4 in a saturable fashion, generating inactive ring‑opened and hydroxylated metabolites. This shift matters clinically because poor CYP2D6 metabolizers—roughly 7% of the Caucasian population—exhibit a three‑fold increase in darifenacin AUC and Cmax. The prescribing information therefore mandates a maximum dose of 7.5 mg·day⁻¹ in patients known to be CYP2D6 poor metabolizers, a stratification not necessitated by tolterodine or solifenacin. However, the lack of active metabolites means that darifenacin’s therapeutic window is not confounded by metabolite accumulation in renal impairment; the product labeling allows use down to creatinine clearance values of 15 mL·min⁻¹ without dose adjustment, based on single‑dose pharmacokinetic studies (n = 24) showing no correlation between CLcr and darifenacin oral clearance.
Solifenacin succinate shares darifenacin’s M₃ preference but produces a more pronounced QT interval prolongation signal. In a thorough QT study performed to ICH E14 standards, darifenacin at steady‑state 30 mg·day⁻¹ (twice the maximum therapeutic dose) produced a placebo‑corrected change from baseline QTcF (ΔΔQTcF) of +3.1 ms (upper 90% CI 7.0 ms), remaining below the 10 ms regulatory threshold of concern. By comparison, published data for solifenacin 30 mg show a ΔΔQTcF of +6.5 ms (upper 90% CI 12.2 ms), necessitating a manufacturer‑recommended dose cap of 10 mg·day⁻¹.
| Parameter | Darifenacin L‑Tartrate | Oxybutynin Chloride | Tolterodine Tartrate | Solifenacin Succinate |
|---|---|---|---|---|
| M₃ Kᵢ (nM) | 0.93 | 2.4 | 2.9 | 1.1 |
| M₃/M₂ selectivity ratio | 60:1 | 2:1 | 1.5:1 | 9:1 |
| Active metabolite contributing to efficacy | None | N‑Desethyloxybutynin (equipotent) | 5‑Hydroxymethyl tolterodine (equipotent) | None |
| P‑gp substrate | Yes | No | Weak | Yes |
| CNS adverse event rate (memory impairment, somnolence) vs placebo at therapeutic dose | 2.6% vs 1.2% | 12.1% vs 2.0% | 3.8% vs 1.7% | 3.1% vs 1.5% |
| QTc prolongation signal at supratherapeutic dose | Below threshold | Not studied at supratherapeutic exposure | Below threshold | Above threshold at 30 mg |
| Dose adjustment in renal impairment | None down to CLcr 15 mL·min⁻¹ | Contraindicated under CLcr 30 mL·min⁻¹ | Reduce by 50% under CLcr 30 | Contraindicated under CLcr 30 mL·min⁻¹ |
The L‑tartrate salt retains a shelf‑life advantage in tropical climates (Zone IVb, ICH stability condition 30 °C/75% RH). Long‑term data through 36 months in simulated commercial packaging show total degradation products below 0.3% and no detectable polymorphic conversion. In contrast, oxybutynin chloride under the same conditions generates N‑desethyloxybutynin at a rate of approximately 0.05% per month, attributable to acid‑catalyzed hydrolysis of the ester linkage when the hydrochloride salt deliquesces above 55% RH.
In manufacturing environments employing high‑shear wet granulation, darifenacin L‑tartrate demonstrates compatibility with extended‑release hydrophilic matrix systems based on hypromellose (Methocel K100M, apparent viscosity of 100,000 mPa·s as a 2% aqueous solution). Dissolution testing in 900 mL phosphate buffer at pH 6.8 using USP apparatus II at 50 rpm yields a f₂ similarity value of 82 between batches stored at 40 °C/75% RH for six months and those stored at 25 °C/60% RH, indicating robust matrix integrity unaffected by microclimate acidification—a failure mode documented for citrate‑containing formulations of alternative salts. Such performance continuity across ICH climatic zones underpins the choice of the L‑tartrate salt for once‑daily controlled‑release presentations targeting developing‑market access.
